4 Canadian Stocks with the Highest Return on Equity

The Canadian stocks on our list have generated superior Return on Equity (ROE) of more than 100%

SmallCapPower | October 2, 2017: Today we have identified four Canadian stocks with high Return on Equity (ROE) ratios of more than 100%. ROE is a measure of profitability of a business in relation to its shareholders’ equity. ROE is a key metric for gauging the success of a company, as it measures of how well it uses investments to generate earnings growth. A high ROE also signifies strong management, as it shows they have allocated shareholders’ capital to high-return projects.

Greenfields Petroleum Corp. (TSXV: GNF)

Greenfields Petroleum Corp. is a junior oil and natural gas exploration and development corporation focused on the development and production of proven oil and gas reserves principally in the Republic of Azerbaijan.

  • TTM Revenues: $30.7 million
  • MarketCap: $28.8 million
  • Return on Equity: 135.8%
  • Price ChgPct YTD: -44.8%

Inter Rock Minerals Inc. (TSXV: IRO)

Inter Rock Minerals Inc explores and mines for mineral reserves in North America and Europe.The Company is engaged in the production and marketing of high purity dolomite throughout the U.S.

  • TTM Revenues: $45.8 million
  • MarketCap: $5.6 million
  • Return on Equity: 124.3%
  • Price Chg Pct YTD:66.7%

 Paramount Resources Ltd. (TSX: POU)

Paramount Resources Ltd. explores and develops unconventional and conventional petroleum and natural gas prospects, including long-term unconventional exploration and pre-development projects, and holds a portfolio of investments in other entities. The Company operates primarily in western Canada.

  • TTM Revenues: $214.1 million
  • MarketCap: $3.2billion
  • Return on Equity: 118.6%
  • Price Chg Pct YTD: 46.1%

Medicure Inc. (TSXV: MPH)

Medicure Inc. is a cardiovascular drug discovery and development company focused on developing therapeutics for unmet needs in the field of cardiovascular medicine.  The Company’s current focus is on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke.

  • TTM Revenues: $53.1 million
  • MarketCap: $125.2 million
  • Return on Equity: 113.7%
  • Price Chg Pct YTD: -22.2%


Disclosure: Neither the author nor any of the principals at SmallCapPower, or their family members, own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below: